Zobrazeno 1 - 10
of 35
pro vyhledávání: '"C Brun—Strang"'
Autor:
Jacques Massol, Alain Puech, Jean-Pierre Boissel, A. Alperovitch, M. Bamberger, B. Bégaud, O. Blin, P. Blin, G. Bréart, C. Brun Strang, M. Buyse, A. Castot, M. Chauvenet, A. Chicoye, N. David, F. De Bels, R. De Sahb Berkovitch, E. Dohin, F. Fagnani, B. Falissard, C. Gastaldi-Menager, I. Giri, M. Haim, J.M. Joubert, M. Lapeyre-Mestre, C. Lassale, I. Marchant Ramirez, F. Meyer, J. Micallef, M. Mollimard, T. Moreau-Defarges, L. Pazart, L. Perret, M. Pigeon, C. Rumeau Pichon, Ph. Tcheng, M. Woler, L. Zanetti, M. Zylberman
Publikováno v:
Therapies. 62:417-425
Resume L’interet de sante publique des medicaments (ISP) est un critere d’evaluation recent (decret d’octobre 1999) et specifiquement francais qui, faute d’elements disponibles au moment de son appreciation, reste a ce jour souvent incomplete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52097f3e2576d994524b4e3f1059511a
https://doi.org/10.2515/therapie:2007072
https://doi.org/10.2515/therapie:2007072
Autor:
Muriel Vray, Bernard Hamelin, Patrice Jaillon, M. Andréjak, R. Benamouzig, J.-P. Boissel, C. Bremard-Oury, C. Brun-Strang, E. Caulin, D. Cellier, D. Costagliola, V. Daurat, A. El Hasnaoui, J.-M. Goehrs, B. Hamelin, P. Jaillon, C. Jouan-Flahault, J.-L. Montastruc, N. Moore, A. Puech, M. Ricatte, P. Ricordeau, M.-H. Rodde-Dunet, E. Rouffiac, T. Simon, P. Simon, A. Spriet, E. Van Ganse, P. Velicitat, M. Vray
Publikováno v:
Therapies. 60:345-349
The respective roles of controlled clinical trials and observational studies (cohort or case-control studies) in evaluating the efficacy, safety and usefulness of a drug were analysed. A randomised, controlled, double-blind study is the best method o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::569e71e509a59ae9da1111b385f1c829
https://doi.org/10.2515/therapie:2005048
https://doi.org/10.2515/therapie:2005048
Autor:
P. Jaillon, E. Caulin, M. Vray, E. Van Ganse, Alain J. Puech, E. Rouffiac, Jean-Pierre Boissel, Jean-Marie Goehrs, M. Ricatte, D. Cellier, C. Brun-Strang, P. Simon, Patrice Jaillon, A. Spriet, Chrystel Jouan-Flahault, M.-H. Rodde-Dunet, Michel Andrejak, Bernard Hamelin, B. Hamelin, Muriel Vray, Tabassome Simon, J. L. Montastruc, Dominique Costagliola, A El Hasnaoui, P. Ricordeau, C. Bremard-Oury, P. Velicitat, Robert Benamouzig, V. Daurat, Nicholas Moore
Publikováno v:
Therapies. 60:339-344
Resume La place relative des essais cliniques comparatifs et des etudes observationnelles (cohortes ou etudes castemoins) a ete etudiee dans l’objectif d’evaluer l’efficacite, la tolerance et l’interet de sante publique d’un medicament. L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab608f0eb393a7b093b5491719086e56
https://doi.org/10.2515/therapie:2005047
https://doi.org/10.2515/therapie:2005047
Autor:
Yvon Lebranchu, G Priol, C Le Pen, H Lilliu, A. Al Najjar, O Reigneau, Mathias Büchler, C Brun-Strang
Publikováno v:
Clinical Transplantation. 18:247-253
Purpose: Based on the data of clinical trial CHI-F-02 comparing the efficacy and safety of basiliximab (Simulect®) vs. anti-thymocyte globulin (Thymoglobulin®) in renal transplant induction, we carried out an economic evaluation. Method: This pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fecc839738486f3bdb52bac7f9ff43e
https://doi.org/10.1111/j.1399-0012.2004.00148.x
https://doi.org/10.1111/j.1399-0012.2004.00148.x
Autor:
Marie Fouchard, Faiez Zannad, E. Autret-Leca, J.-P. Bader, M. Bellet, J.-F. Bergmann, M. Bernard-Harlaud, C. Bernaud, R. Bordet, G. Bouvenot, C. Brun-Strang, A. Castaigne, N. Dumarcet, E. Eschwège, M. Gallard, I. Giri, B. Hamelin, A. Jeanblanc, P. Jolliet, H. Kolsky, D. Lagarde, G. Lapeyre, C. Lassale, J.-P. Lehner, H. Lelouët, M. Malbezin, S. Paulmier-Bigot, M. Pigeon, S. Ravoire, P. Ricordeau, B. Rouveix, J. Soletti, S. Tardieu, J.-L. Thomas, C. Thuillez
Publikováno v:
Therapies. 59:323-328
The round table elected to focus its discussion on trials that, in terms of their importance, are likely to modify medical practices and behaviour. Such trials may be pre- or postmarketing studies. For the findings of a trial to result in a change in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bdafdfab1745bbb29bf6a7a6c4bb6ae
https://doi.org/10.2515/therapie:2004061
https://doi.org/10.2515/therapie:2004061
Autor:
Marie Fouchard, Faiez Zannad, E. Autret-Leca, J.-P. Bader, M. Bellet, J.-F. Bergmann, M. Bernard-Harlaud, C. Bernaud, R. Bordet, G. Bouvenot, C. Brun-Strang, A. Castaigne, N. Dumarcet, E. Eschwège, M. Gallard, I. Giri, B. Hamelin, A. Jeanblanc, P. Jolliet, H. Kolsky, D. Lagarde, G. Lapeyre, C. Lassale, J.-P. Lehner, H. Lelouët, M. Malbezin, S. Paulmier-Bigot, M. Pigeon, S. Ravoire, P. Ricordeau, B. Rouveix, J. Soletti, S. Tardieu, J.-L. Thomas, C. Thuillez
Publikováno v:
Therapies. 59:317-322
Resume La table ronde a choisi d’orienter sa discussion sur les essais qui, par leur importance, sont susceptibles de modifier les pratiques medicales et les comportements. Ces essais peuvent etre pre- ou post-AMM (autorisation de mise sur le march
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ef35df44fc0eebe5f032b3f3d6cdcf
https://doi.org/10.2515/therapie:2004060
https://doi.org/10.2515/therapie:2004060
Autor:
Jacques Massol, Alain Puech, Jean-Pierre Boissel, A. Alperovitch, M. Bamberger, B. Begaud, O. Blin, P. Blin, G. Breart, C. Brun Strang, M. Buyse, A. Castot, M. Chauvenet, A. Chicoye, N. David, F. De Bels, R. De Sahb Berkovitch, E. Dohin, F. Fagnani, B. Falissard, C. Gastaldi-Menager, I. Giri, M. Haim, J.M. Joubert, M. Lapeyre-Mestre, C. Lassale, I. Marchant Ramirez, F. Meyer, J. Micallef, M. Mollimard, T. Moreau-Defarges, L. Pazart, L. Perret, M. Pigeon, C. Rumeau Pichon, Ph. Tcheng, M. Woler, L. Zanetti, M. Zylberman
Publikováno v:
Therapie. 62(5)
The Public Health Benefit (PHB) of new medicines is a recent and French-specific criterion (October 1999 decree) which is often only partially documented in the transparency files due to a lack of timely information. At the time of the first reimburs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea6955521c2706cae53871fb8586e0
https://pubmed.ncbi.nlm.nih.gov/18206104
https://pubmed.ncbi.nlm.nih.gov/18206104
Publikováno v:
Value in Health. 5(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945021bff06a64bc1035d7b782bfd733
Autor:
C Brun—Strang, M Ziegler
Publikováno v:
Value in Health. 6:769-770
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd99649556e471a007a203f251867eed
https://doi.org/10.1016/s1098-3015(10)61961-4
https://doi.org/10.1016/s1098-3015(10)61961-4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.